Showing 141 - 160 results of 101,477 for search '(( 5 non decrease ) OR ( 5 ((step decrease) OR (((we decrease) OR (a decrease)))) ))', query time: 1.71s Refine Results
  1. 141
  2. 142
  3. 143
  4. 144
  5. 145
  6. 146
  7. 147
  8. 148
  9. 149
  10. 150
  11. 151

    Table_1_Cysteinyl Leukotriene Receptor Antagonists Associated With a Decreased Incidence of Cancer: A Retrospective Cohort Study.docx by Ha Young Jang (1522204)

    Published 2022
    “…The cancer risk showed a tendency to decrease rapidly when LTRAs were used in high dose (aHR = 0.56, 95% CI = 0.40–0.79) or for longer durations of more than 3 years (aHR = 0.68, 95% CI = 0.60–0.76) and 5 years (aHR = 0.33, 95% CI = 0.26–0.42). …”
  12. 152
  13. 153
  14. 154
  15. 155
  16. 156
  17. 157

    Data_Sheet_1_Improved body composition decreases the fat content in non-alcoholic fatty liver disease, a meta-analysis and systematic review of longitudinal studies.docx by Dóra Mátis (15407060)

    Published 2023
    “…Background<p>Based on cross-sectional studies, there is a link between body composition parameters and steatosis in non-alcoholic fatty liver disease (NAFLD). …”
  18. 158

    Different response of visASCs to a micro-local oxygen concentration decrease in metabolically active sites of the adipose tissue. by Wilfredo Oliva-Olivera (301968)

    Published 2017
    “…However, hypox-visASCs from MS patients show a lower ability to actively participate in or stimulate the formation of microvascular structures, while they favor the accumulation of CD11C<sup>+</sup> and CD163<sup>+</sup> macrophages in the adipose tissue through their contribution to the increased tissue levels of MCP1. ↑ Increased response; <b>↓</b> Decreased response; → Hypox-visASCs main response NonMS: obese subjects without metabolic syndrome; MS: obese subjects with metabolic syndrome; visASC: visceral adipose tissue-derived multipotent mesenchymal cells; hypox-visASCs: visASC under hypoxia; NOX5: NADPH Oxidase 5; SDF1α: stromal cell-derived factor 1α; VEGF: vascular endothelial growth factor; MCP1: monocyte chemoattractant protein 1; CD11C<sup>+</sup>, CD163<sup>+</sup>: proinflammatory macrophage cell-surface markers.…”
  19. 159
  20. 160